Long-term Oral Tacrolimus Therapy in Refractory to Infliximab Fistulizing Crohnʼs Disease.

200578 citationsJournal Articlebronze Open Access

Authors

Yago González‐Lama · Hospital Universitario Puerta de Hierro Majadahonda

Luis Abreu · Hospital Universitario Puerta de Hierro Majadahonda

María Isabel Vera-Muñoz · Hospital Universitario Puerta de Hierro Majadahonda

Miguel Pastrana · Hospital Universitario Puerta de Hierro Majadahonda

Susana Tabernero · Hospital Universitario Puerta de Hierro Majadahonda

Juan de la Revilla · Hospital Universitario Puerta de Hierro Majadahonda

Abstract

Oral tacrolimus could be an effective and safe treatment for patients with FCD, even if there has been no response to infliximab treatment. Randomized studies are needed to compare oral tacrolimus with infliximab in terms of efficacy, safety, and costs.

Topics & Keywords

Inflammatory Bowel Disease Autoimmune and Inflammatory Disorders Diverticular Disease and Complications

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Inflammatory Bowel Diseases

Volume 11, Issue 1, pp. 8-15

DOI: 10.1097/00054725-200501000-00002

Field-Weighted Citation Impact: 4.16